KDR and nonpapillary renal cell carcinoma: Currently, the standard of care treatment approaches for most ccRCC patients include either a dual regimen of immune checkpoint inhibitors (ICIs) (ipilimumab/nivolumab) or an ICI combined with tyrosine kinase inhibitors (TKIs) targeting the Vascular Endothelial Growth Factor Receptor (VEGF‐R) (e.g., Pembrolizumab/Axitinib) [4].